Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegavirales. The Filoviridae family comprises three genera: Ebola virus, Marburg virus and Cueva virus. The Ebola virus genus is further subdivided into five species, each represented by a unique virus: Taï Forest Ebola virus (TAFV), Reston Ebola virus (RESTV), Sudan Ebola virus (SUDV), Bundibugyo Ebola virus (BDBV), and Zaire Ebola virus (EBOV). EBOV is the most prominent of these.

BDBV is considered a less virulent Ebola virus due to its lower case fatality rate in human and animal outbreaks (25% to 51%). In contrast, the case fatality rate following Ebola virus infection in non-human primates is almost always fatal. While in-depth transcriptomic analyses have been conducted on samples from human patients and non-human primates infected with the Ebola virus, no such studies have been conducted on the Bundibugyo virus.

The clinical manifestations of Ebola virus infection in humans and non-human primates (NHPs) are similar and include viremia, cytokine storm and consumptive coagulopathy, which can lead to septic shock and multiple organ failure. The virus initially replicates in monocytes and dendritic cells before spreading to hepatocytes, endothelial cells and epithelial cells.

In May 2026, the World Health Organization (WHO) received a report of a highly fatal Bondibougio virus outbreak in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), which resulted in deaths among healthcare workers. The Bondibougio virus forms filamentous viral particles and is closely related to the Zaire Ebola virus. It is one of several viruses that can cause Ebola in humans, presenting as viral haemorrhagic fever. Unlike Ebola virus disease, there are currently no approved vaccines or specific treatments for the Bondibougio virus, but early supportive care can save lives. This outbreak has once again drawn global attention to Ebola, highlighting the urgent need to develop effective diagnostic and preventive products.

Recognizing the urgent need for more effective tools to combat BDBV, Creative Diagnostics is monitoring the current outbreak closely and has swiftly introduced a range of products to support BDBV infection and vaccine research, including antibodies, ELISA kits, RT-PCR kits, and nucleic acid standard references.

Creative Diagnostics will continue to provide research solutions to assist scientists, public health researchers and biotechnology organizations in deeper understanding of this emerging pathogen. To learn more about Creative Diagnostics’ research products and outbreak response reagents, please visit https://www.creative-diagnostics.com/bundibugyo-virus-bdbv-outbreak-response.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Lysosomes are essential organelles in eukaryotic cells that are responsible for a variety of functions, including endocytic degradation, extracellular secretion, and signal transduction. Dozens of proteins are localized to the lysosomal membrane, where they regulate the transport of ions and substances across the membrane. These proteins are crucial to lysosomal function. Mutations or abnormal expression of these proteins can trigger various diseases, making them potential targets for the development of drugs aimed at treating lysosomal disorders. However, further breakthroughs in this field of research require a deeper understanding of the underlying mechanisms by which abnormalities in these membrane proteins induce associated diseases.

As complex drug modalities such as antibody-drug conjugates (ADCs) and oligonucleotide therapies (including mRNA, siRNA and circular RNA) dominate the preclinical development pipeline, it is of paramount importance to understand their intracellular fate. A major bottleneck in these workflows is the in vitro simulation of the lysosomal environment. Due to physical density overlap, standard differential centrifugation often contaminates lysosomal fractions with mitochondria, which distorts metabolic and pharmacokinetic data.

To support this research, Creative Diagnostics has overcome this technical challenge with its TriLS Tritosome separation technology. This technology uses the tissue-specific endocytosis of the non-ionic surfactant Tyloxapol (Triton WR-1339) to selectively alter the buoyant density of target lysosomes. This enables pure, high-resolution separation via density gradient centrifugation, effectively removing over 90% of mitochondrial cross-contamination while preserving active lysosomal hydrolases.

The Tritosomes supplied by Creative Diagnostics play a key role in advancing research into ADCs by providing a pure model for the study of lysosomal uptake, processing, and payload release. Tritosomes enable researchers to gain in-depth knowledge of linker chemistry, cleavage efficiency, payload release patterns and species-specific differences in drug release. This helps to optimize the stability and efficacy of ADCs, achieving better therapeutic outcomes.

A key challenge in the research of small-molecule nucleic acid drugs is that most oligonucleotides are captured by endosomes and lysosomes. If they cannot escape these organelles and enter the cytoplasm, they are rapidly degraded and lose their therapeutic activity. Against this backdrop, Creative Diagnostics' Tritosomes provide a controlled in vitro system for studying the degradation kinetics of unmodified and chemically modified nucleic acid drugs.

Researchers can use these Tritosomes to evaluate the protective effect of chemical modifications against lysosomal degradation and assess the efficacy of delivery systems designed to facilitate endosomal escape. Consequently, Creative Diagnostics' Tritosomes are crucial for optimizing drug stability and refining delivery strategies prior to progressing to more complex animal models.

To explore technical specifications, review workflow diagrams, or request a quote, please visit the official product page at https://qbd.creative-diagnostics.com/trils-tritosome.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

https://qbd.creative-diagnostics.com/trils-tritosome.html

Hantaviruses are emerging zoonotic pathogens that belong to the Bunyaviridae family. The US Centers for Disease Control and Prevention (CDC) classifies them as Category A pathogens. They pose a serious threat to human health as their infection can lead to haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS), both of which are highly fatal. These pathogens are transmitted to humans via aerosols containing the excreta of infected rodent hosts.

Hantaviruses possess a tripartite negative-strand RNA genome. The three genomic RNA segments (S, M and L) encode